Categories
Change Password!
Reset Password!
Long-term safety data on potassium-competitive acid blockers (P-CABs) remain restricted, particularly regarding their effects on serum gastrin levels during maintenance therapy.
During long-term GERD maintenance therapy, half-dose tegoprazan consistently maintains lower serum gastrin levels and minimizes the incidence of hypergastrinemia compared with lansoprazole, indicating a more favorable safety profile.
Long-term safety data on potassium-competitive acid blockers (P-CABs) remain restricted, particularly regarding their effects on serum gastrin levels during maintenance therapy. This study investigated tegoprazan's impact on gastrin secretion during maintenance treatment of gastroesophageal reflux disease (GERD), and compared its safety profile with the proton pump inhibitor (PPI) lansoprazole.
This prospective, randomized clinical trial recruited patients who initially received standard-dose PPI therapy (n = 121) or tegoprazan (n = 226) for GERD management. Following initial treatment, subjects were randomized to half-dose tegoprazan (n = 173) or lansoprazole (n = 174) for maintenance therapy lasting up to 24 weeks. Serum gastrin concentrations were assessed immediately following induction therapy and serially monitored throughout the maintenance phase.
Baseline serum gastrin levels were comparable between lansoprazole and tegoprazan groups. During maintenance therapy, those receiving tegoprazan illustrated considerably lower gastrin levels at week 16 and week 24 compared with those treated with lansoprazole. While the baseline prevalence of hypergastrinemia (>115 pg/mL) did not differ markedly between groups, the incidence was markedly reduced in the tegoprazan group during maintenance treatment at weeks 8, 16, and 24. Multivariate analysis identified age, sex, baseline gastrin levels, Helicobacter pylori (H.pylori) infection status, and treatment group as independent predictors of final gastrin concentrations.
Compared with lansoprazole, tegoprazan was linked with a lower elevation in serum gastrin levels and a reduced risk of hypergastrinemia during GERD maintenance therapy. These findings suggest that half-dose tegoprazan may offer a safer long-term acid suppression strategy, potentially minimizing gastrin-related safety concerns related to chronic acid-suppressive treatment.
Journal of Neurogastroenterology and Motility
The Effect of Tegoprazan on Serum Gastrin Levels and the Development of Hypergastrinemia in the Maintenance Treatment for Gastroesophageal Reflux Disease: Comparison to Lansoprazole
Kwang Jae Lee et al.
Comments (0)